These results demonstrated that IGF1R inhibitor linsitinib combined with PTK2 inhibitor defactinib prominently suppressed BACH1-induced HCC metastasis, providing a promising combination strategy for HCC therapy. This evidence concerns the gene IGF1R and hepatocellular carcinoma.